Augurex - Personalized Medicine Drug Target Extracellular - Arthritis

In the development of RA and other inflammatory types of arthritis, multiple factors contribute to disease processes to varying degrees in different patients. 14-3-3η is recognized as a new factor within this process and represents a rationale drug target for personalized medicine alongside its 14-3-3η companion biomarker portfolio described above. Augurex preclinical animal studies to date demonstrate that anti-14-3-3η monoclonal antibodies delay the onset of and mitigate the severity of arthritis development. This continued research has the potential to produce the first true personalized medicine in RA, wherein patients with varying levels of 14-3-3η measured by the companion biomarkers, can be optimally dosed with the anti-14-3-3η therapy and monitored for clearance of the protein and maintenance of negative levels along the disease course.